Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

Nanobiotix announced promising Part 1 data from the CONVERGE Phase 2 study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer, in stage 3 inoperable non-small cell lung cancer. Results showed an 85.7% overall response rate and 57.1% complete response rate in 7 patients receiving the treatment combined with concurrent chemoradiotherapy and durvalumab, significantly exceeding the <5% complete response rate of standard care.